etidronate has been researched along with Femoral Fractures in 13 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Femoral Fractures: Fractures of the femur.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates." | 1.38 | Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. ( Abrahamsen, B; Pazianas, M; Russell, RG; Wang, Y, 2012) |
| "Alendronate (aln) is a potent bisphosphonate with a prolonged duration of action." | 1.35 | Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. ( Abrahamsen, B; Eastell, R; Eiken, P, 2009) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gopal, GK | 1 |
| Tam, KL | 1 |
| Krishnan, SP | 1 |
| Maddern, IL | 1 |
| Schilcher, J | 2 |
| Koeppen, V | 1 |
| Aspenberg, P | 2 |
| Michaëlsson, K | 1 |
| Abrahamsen, B | 2 |
| Eiken, P | 1 |
| Eastell, R | 1 |
| Girgis, CM | 1 |
| Sher, D | 1 |
| Seibel, MJ | 1 |
| Fahlgren, A | 1 |
| Osugi, K | 1 |
| Miwa, S | 1 |
| Marukawa, S | 1 |
| Marukawa, K | 1 |
| Kawaguchi, Y | 1 |
| Nakato, S | 1 |
| Kľoc, P | 1 |
| Tomčovčík, L | 1 |
| Kľoc, J | 1 |
| Ott, SM | 1 |
| Pazianas, M | 1 |
| Wang, Y | 1 |
| Russell, RG | 1 |
| Hoppé, E | 1 |
| Masson, C | 1 |
| Laffitte, A | 1 |
| Chappard, D | 1 |
| Audran, M | 1 |
| Minne, HW | 1 |
| Pollähne, W | 1 |
| Pfeifer, M | 1 |
| Begerow, B | 1 |
| Hinz, C | 1 |
| Pertuiset, E | 1 |
| Mautalen, C | 1 |
| Gonzalez, D | 1 |
| Blumenfeld, EL | 1 |
| Santini Araujo, E | 1 |
| Schajowicz, F | 1 |
1 review available for etidronate and Femoral Fractures
| Article | Year |
|---|---|
What is the optimal duration of bisphosphonate therapy?
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Femoral F | 2011 |
12 other studies available for etidronate and Femoral Fractures
| Article | Year |
|---|---|
Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Femoral | 2014 |
Risk of atypical femoral fracture during and after bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Cohort | 2015 |
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Cohort Studies; Cross-Sectional Studies; Denmark; Etidronic Ac | 2009 |
Atypical femoral fractures and bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Hum | 2010 |
Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.
Topics: Alendronate; Bone Density Conservation Agents; Bone Nails; Bone Resorption; Etidronic Acid; Female; | 2010 |
Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Femoral Fractures; Frac | 2011 |
[Bilateral pathological sub-trochanteric fracture in a long-term biphosphonate user].
Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Femoral Fractures; Fractures, Sponta | 2011 |
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Topics: Administration, Oral; Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedul | 2012 |
Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate.
Topics: Aged, 80 and over; Alkaline Phosphatase; Biopsy; Bone Density Conservation Agents; Calcification, Ph | 2012 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
[Treatment of common osteoporosis].
Topics: Aged; Estrogens; Etidronic Acid; Female; Femoral Fractures; Humans; Middle Aged; Osteoporosis, Postm | 1991 |
Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate (EHDP).
Topics: Aged; Etidronic Acid; Female; Femoral Fractures; Femoral Neck Fractures; Fractures, Spontaneous; Hum | 1986 |